Don't Miss: Best Chance to Access Midcap Stocks Research at 80% OFF
Here is the latest financial fact sheet of IPCA LABS. For more details, see the IPCA LABS quarterly results and IPCA LABS share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 0.8 |
No. of shares | m | 253.70 |
1 Week | % | 2.2 |
1 Month | % | 16.0 |
1 Year | % | 66.0 |
52 week H/L | Rs | 1,374.0/670.0 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
IPCA LABS EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 1,042 | 1,616 | 2,456 | 2,767 | 1,062 | |
Low | Rs | 590 | 844 | 1,371 | 917 | 768 | |
Sales per share (Unadj.) | Rs | 294.3 | 363.2 | 423.3 | 227.2 | 243.0 | |
Earnings per share (Unadj.) | Rs | 35.0 | 47.8 | 90.6 | 35.9 | 19.4 | |
Diluted earnings per share | Rs | 17.4 | 23.8 | 45.3 | 35.9 | 19.4 | |
Cash flow per share (Unadj.) | Rs | 49.4 | 64.4 | 107.1 | 45.1 | 29.7 | |
Dividends per share (Unadj.) | Rs | 1.50 | 2.50 | 4.00 | 4.00 | 4.00 | |
Adj. dividends per share | Rs | 0.75 | 1.25 | 2.00 | 4.00 | 4.00 | |
Avg Dividend yield | % | 0.2 | 0.2 | 0.2 | 0.2 | 0.4 | |
Book value per share (Unadj.) | Rs | 247.1 | 286.2 | 370.6 | 215.4 | 230.3 | |
Adj. book value per share | Rs | 123.1 | 142.5 | 185.3 | 215.4 | 230.3 | |
Shares outstanding (eoy) | m | 126.35 | 126.35 | 126.85 | 253.70 | 253.70 | |
Price / Sales ratio | x | 2.8 | 3.4 | 4.5 | 8.1 | 3.8 | |
Avg P/E ratio | x | 23.3 | 25.7 | 21.1 | 51.3 | 47.2 | |
P/CF ratio (eoy) | x | 16.5 | 19.1 | 17.9 | 40.9 | 30.8 | |
Price / Book Value ratio | x | 3.3 | 4.3 | 5.2 | 8.6 | 4.0 | |
Dividend payout | % | 4.3 | 5.2 | 4.4 | 11.1 | 20.6 | |
Avg Mkt Cap | Rs m | 103,110 | 155,407 | 242,728 | 467,336 | 232,120 | |
Total wages/salary | Rs m | 7,874 | 9,212 | 10,136 | 11,774 | 12,876 |
IPCA LABS INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 37,182 | 45,894 | 53,699 | 57,637 | 61,642 | |
Other income | Rs m | 747 | 865 | 1,292 | 1,217 | 1,518 | |
Total revenues | Rs m | 37,929 | 46,759 | 54,991 | 58,854 | 63,160 | |
Gross profit | Rs m | 6,765 | 8,827 | 14,812 | 12,576 | 9,033 | |
Depreciation | Rs m | 1,824 | 2,105 | 2,092 | 2,324 | 2,616 | |
Interest | Rs m | 222 | 198 | 123 | 112 | 482 | |
Profit before tax | Rs m | 5,465 | 7,389 | 13,890 | 11,357 | 7,453 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 1,042 | 1,353 | 2,401 | 2,248 | 2,534 | |
Profit after tax | Rs m | 4,422 | 6,036 | 11,488 | 9,110 | 4,919 | |
Gross profit margin | % | 18.2 | 19.2 | 27.6 | 21.8 | 14.7 | |
Effective tax rate | % | 19.1 | 18.3 | 17.3 | 19.8 | 34.0 | |
Net profit margin | % | 11.9 | 13.2 | 21.4 | 15.8 | 8.0 |
IPCA LABS BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 23,778 | 28,557 | 34,370 | 44,467 | 51,893 | |
Current liabilities | Rs m | 10,975 | 13,264 | 11,605 | 14,659 | 18,058 | |
Net working cap to sales | % | 34.4 | 33.3 | 42.4 | 51.7 | 54.9 | |
Current ratio | x | 2.2 | 2.2 | 3.0 | 3.0 | 2.9 | |
Inventory Days | Days | 25 | 36 | 49 | 74 | 51 | |
Debtors Days | Days | 7 | 7 | 6 | 6 | 6 | |
Net fixed assets | Rs m | 21,711 | 24,021 | 26,295 | 31,643 | 34,336 | |
Share capital | Rs m | 253 | 253 | 254 | 254 | 254 | |
"Free" reserves | Rs m | 30,971 | 35,903 | 46,763 | 54,395 | 58,167 | |
Net worth | Rs m | 31,224 | 36,155 | 47,017 | 54,648 | 58,420 | |
Long term debt | Rs m | 1,409 | 1,030 | 91 | 3,952 | 6,518 | |
Total assets | Rs m | 45,488 | 52,578 | 60,664 | 76,215 | 86,229 | |
Interest coverage | x | 25.6 | 38.4 | 114.2 | 102.4 | 16.5 | |
Debt to equity ratio | x | 0 | 0 | 0 | 0.1 | 0.1 | |
Sales to assets ratio | x | 0.8 | 0.9 | 0.9 | 0.8 | 0.7 | |
Return on assets | % | 10.2 | 11.9 | 19.1 | 12.1 | 6.3 | |
Return on equity | % | 14.2 | 16.7 | 24.4 | 16.7 | 8.4 | |
Return on capital | % | 17.4 | 20.4 | 29.7 | 19.6 | 12.2 | |
Exports to sales | % | 46.6 | 46.7 | 50.6 | 43.4 | 42.9 | |
Imports to sales | % | 16.9 | 16.8 | 14.8 | 15.5 | 13.3 | |
Exports (fob) | Rs m | 17,308 | 21,438 | 27,172 | 25,027 | 26,434 | |
Imports (cif) | Rs m | 6,266 | 7,694 | 7,949 | 8,935 | 8,178 | |
Fx inflow | Rs m | 17,308 | 21,438 | 27,172 | 25,027 | 26,434 | |
Fx outflow | Rs m | 6,266 | 7,694 | 7,949 | 8,935 | 8,178 | |
Net fx | Rs m | 11,042 | 13,743 | 19,223 | 16,092 | 18,257 |
IPCA LABS CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 5,010 | 5,704 | 10,901 | 8,561 | 8,058 | |
From Investments | Rs m | -1,651 | -5,097 | -5,207 | -8,551 | -7,250 | |
From Financial Activity | Rs m | -1,832 | -1,365 | -3,058 | 4,268 | 5,072 | |
Net Cashflow | Rs m | 1,528 | -755 | 2,636 | 4,319 | 5,881 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Premchand Godha | COMP SEC: Harish P Kamath | YEAR OF INC: 1949 | BSE CODE: 524494 | FV (Rs): 1 | DIV YIELD (%): 0.3 |
Read: IPCA LABS 2022-23 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare IPCA LABS With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
It was indeed a volatile trading session for Indian share markets yesterday.